Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
36
DYN Quote, Financials, Valuation and Earnings
Last price:
$15.55
Seasonality move
:
-6.57%
Day range:
$15.80 - $16.71
52-week range:
$6.36 - $25.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.81x
Volume:
2.2M
Avg. volume:
2.1M
1-year change:
14.94%
Market cap:
$2.6B
Revenue:
--
EPS (TTM):
-$3.66
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
DYN
Dyne Therapeutics, Inc.
|
-- | -$0.76 | -- | -22.51% | $39.13 |
|
GPCR
Structure Therapeutics, Inc.
|
-- | -$0.36 | -- | -55.6% | $107.80 |
|
MNKD
MannKind Corp.
|
$99.9M | $0.03 | 30.05% | 17.65% | $9.61 |
|
PTGX
Protagonist Therapeutics, Inc.
|
$14.9M | -$0.54 | -23.52% | -191.66% | $101.92 |
|
RNA
Avidity Biosciences, Inc.
|
$2M | -$1.26 | -33.35% | -58.11% | $74.64 |
|
SRPT
Sarepta Therapeutics, Inc.
|
$391M | -$0.77 | -49.33% | -91.57% | $21.43 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
DYN
Dyne Therapeutics, Inc.
|
$16.00 | $39.13 | $2.6B | -- | $0.00 | 0% | -- |
|
GPCR
Structure Therapeutics, Inc.
|
$72.04 | $107.80 | $5.1B | -- | $0.00 | 0% | -- |
|
MNKD
MannKind Corp.
|
$5.63 | $9.61 | $1.7B | 59.77x | $0.00 | 0% | 5.54x |
|
PTGX
Protagonist Therapeutics, Inc.
|
$81.93 | $101.92 | $5.1B | 129.37x | $0.00 | 0% | 25.13x |
|
RNA
Avidity Biosciences, Inc.
|
$72.91 | $74.64 | $11B | -- | $0.00 | 0% | 458.78x |
|
SRPT
Sarepta Therapeutics, Inc.
|
$17.40 | $21.43 | $1.8B | 20.50x | $0.00 | 0% | 0.74x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
DYN
Dyne Therapeutics, Inc.
|
14.83% | 1.729 | 6.68% | 13.23x |
|
GPCR
Structure Therapeutics, Inc.
|
0.91% | 0.111 | 0.44% | 13.89x |
|
MNKD
MannKind Corp.
|
124.56% | -0.068 | 13.7% | 2.54x |
|
PTGX
Protagonist Therapeutics, Inc.
|
1.64% | -0.620 | 0.26% | 12.83x |
|
RNA
Avidity Biosciences, Inc.
|
2.58% | 0.508 | 0.78% | 11.04x |
|
SRPT
Sarepta Therapeutics, Inc.
|
48.64% | -0.463 | 61.92% | 1.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
DYN
Dyne Therapeutics, Inc.
|
-$500K | -$113.9M | -59.17% | -64.85% | -- | -$110M |
|
GPCR
Structure Therapeutics, Inc.
|
-$978.3K | -$73.9M | -25.36% | -25.55% | -- | -$52.6M |
|
MNKD
MannKind Corp.
|
$61.9M | $18.8M | 24.75% | -- | 22.86% | $22.4M |
|
PTGX
Protagonist Therapeutics, Inc.
|
$4.4M | -$46.4M | 7.03% | 7.15% | -985.17% | -$2M |
|
RNA
Avidity Biosciences, Inc.
|
$11.4M | -$188.8M | -37.09% | -37.47% | -1513.48% | -$156.9M |
|
SRPT
Sarepta Therapeutics, Inc.
|
$230.1M | -$62.9M | -10.24% | -20.67% | -15.75% | -$55.6M |
Dyne Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns DYN or GPCR?
Structure Therapeutics, Inc. has a net margin of -- compared to Dyne Therapeutics, Inc.'s net margin of --. Dyne Therapeutics, Inc.'s return on equity of -64.85% beat Structure Therapeutics, Inc.'s return on equity of -25.55%.
Company Gross Margin Earnings Per Share Invested Capital DYNDyne Therapeutics, Inc.-- -$0.76 $812.2M GPCRStructure Therapeutics, Inc.-- -$1.13 $777.1M -
What do Analysts Say About DYN or GPCR?
Dyne Therapeutics, Inc. has a consensus price target of $39.13, signalling upside risk potential of 144.53%. On the other hand Structure Therapeutics, Inc. has an analysts' consensus of $107.80 which suggests that it could grow by 49.64%. Given that Dyne Therapeutics, Inc. has higher upside potential than Structure Therapeutics, Inc., analysts believe Dyne Therapeutics, Inc. is more attractive than Structure Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DYNDyne Therapeutics, Inc.11 2 0 GPCRStructure Therapeutics, Inc.11 0 0 -
Is DYN or GPCR More Risky?
Dyne Therapeutics, Inc. has a beta of 1.302, which suggesting that the stock is 30.201% more volatile than S&P 500. In comparison Structure Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock DYN or GPCR?
Dyne Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Structure Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dyne Therapeutics, Inc. pays -- of its earnings as a dividend. Structure Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DYN or GPCR?
Dyne Therapeutics, Inc. quarterly revenues are --, which are smaller than Structure Therapeutics, Inc. quarterly revenues of --. Dyne Therapeutics, Inc.'s net income of -$108M is lower than Structure Therapeutics, Inc.'s net income of -$65.8M. Notably, Dyne Therapeutics, Inc.'s price-to-earnings ratio is -- while Structure Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dyne Therapeutics, Inc. is -- versus -- for Structure Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DYNDyne Therapeutics, Inc.-- -- -- -$108M GPCRStructure Therapeutics, Inc.-- -- -- -$65.8M
-
Which has Higher Returns DYN or MNKD?
MannKind Corp. has a net margin of -- compared to Dyne Therapeutics, Inc.'s net margin of 9.72%. Dyne Therapeutics, Inc.'s return on equity of -64.85% beat MannKind Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital DYNDyne Therapeutics, Inc.-- -$0.76 $812.2M MNKDMannKind Corp.75.4% $0.03 $181.4M -
What do Analysts Say About DYN or MNKD?
Dyne Therapeutics, Inc. has a consensus price target of $39.13, signalling upside risk potential of 144.53%. On the other hand MannKind Corp. has an analysts' consensus of $9.61 which suggests that it could grow by 70.71%. Given that Dyne Therapeutics, Inc. has higher upside potential than MannKind Corp., analysts believe Dyne Therapeutics, Inc. is more attractive than MannKind Corp..
Company Buy Ratings Hold Ratings Sell Ratings DYNDyne Therapeutics, Inc.11 2 0 MNKDMannKind Corp.8 0 0 -
Is DYN or MNKD More Risky?
Dyne Therapeutics, Inc. has a beta of 1.302, which suggesting that the stock is 30.201% more volatile than S&P 500. In comparison MannKind Corp. has a beta of 0.839, suggesting its less volatile than the S&P 500 by 16.131%.
-
Which is a Better Dividend Stock DYN or MNKD?
Dyne Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MannKind Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dyne Therapeutics, Inc. pays -- of its earnings as a dividend. MannKind Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DYN or MNKD?
Dyne Therapeutics, Inc. quarterly revenues are --, which are smaller than MannKind Corp. quarterly revenues of $82.1M. Dyne Therapeutics, Inc.'s net income of -$108M is lower than MannKind Corp.'s net income of $8M. Notably, Dyne Therapeutics, Inc.'s price-to-earnings ratio is -- while MannKind Corp.'s PE ratio is 59.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dyne Therapeutics, Inc. is -- versus 5.54x for MannKind Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DYNDyne Therapeutics, Inc.-- -- -- -$108M MNKDMannKind Corp.5.54x 59.77x $82.1M $8M
-
Which has Higher Returns DYN or PTGX?
Protagonist Therapeutics, Inc. has a net margin of -- compared to Dyne Therapeutics, Inc.'s net margin of -834.87%. Dyne Therapeutics, Inc.'s return on equity of -64.85% beat Protagonist Therapeutics, Inc.'s return on equity of 7.15%.
Company Gross Margin Earnings Per Share Invested Capital DYNDyne Therapeutics, Inc.-- -$0.76 $812.2M PTGXProtagonist Therapeutics, Inc.92.34% -$0.62 $656.2M -
What do Analysts Say About DYN or PTGX?
Dyne Therapeutics, Inc. has a consensus price target of $39.13, signalling upside risk potential of 144.53%. On the other hand Protagonist Therapeutics, Inc. has an analysts' consensus of $101.92 which suggests that it could grow by 24.4%. Given that Dyne Therapeutics, Inc. has higher upside potential than Protagonist Therapeutics, Inc., analysts believe Dyne Therapeutics, Inc. is more attractive than Protagonist Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DYNDyne Therapeutics, Inc.11 2 0 PTGXProtagonist Therapeutics, Inc.8 1 0 -
Is DYN or PTGX More Risky?
Dyne Therapeutics, Inc. has a beta of 1.302, which suggesting that the stock is 30.201% more volatile than S&P 500. In comparison Protagonist Therapeutics, Inc. has a beta of 2.264, suggesting its more volatile than the S&P 500 by 126.409%.
-
Which is a Better Dividend Stock DYN or PTGX?
Dyne Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protagonist Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dyne Therapeutics, Inc. pays -- of its earnings as a dividend. Protagonist Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DYN or PTGX?
Dyne Therapeutics, Inc. quarterly revenues are --, which are smaller than Protagonist Therapeutics, Inc. quarterly revenues of $4.7M. Dyne Therapeutics, Inc.'s net income of -$108M is lower than Protagonist Therapeutics, Inc.'s net income of -$39.3M. Notably, Dyne Therapeutics, Inc.'s price-to-earnings ratio is -- while Protagonist Therapeutics, Inc.'s PE ratio is 129.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dyne Therapeutics, Inc. is -- versus 25.13x for Protagonist Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DYNDyne Therapeutics, Inc.-- -- -- -$108M PTGXProtagonist Therapeutics, Inc.25.13x 129.37x $4.7M -$39.3M
-
Which has Higher Returns DYN or RNA?
Avidity Biosciences, Inc. has a net margin of -- compared to Dyne Therapeutics, Inc.'s net margin of -1398.33%. Dyne Therapeutics, Inc.'s return on equity of -64.85% beat Avidity Biosciences, Inc.'s return on equity of -37.47%.
Company Gross Margin Earnings Per Share Invested Capital DYNDyne Therapeutics, Inc.-- -$0.76 $812.2M RNAAvidity Biosciences, Inc.91.54% -$1.27 $1.9B -
What do Analysts Say About DYN or RNA?
Dyne Therapeutics, Inc. has a consensus price target of $39.13, signalling upside risk potential of 144.53%. On the other hand Avidity Biosciences, Inc. has an analysts' consensus of $74.64 which suggests that it could grow by 2.37%. Given that Dyne Therapeutics, Inc. has higher upside potential than Avidity Biosciences, Inc., analysts believe Dyne Therapeutics, Inc. is more attractive than Avidity Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DYNDyne Therapeutics, Inc.11 2 0 RNAAvidity Biosciences, Inc.2 12 0 -
Is DYN or RNA More Risky?
Dyne Therapeutics, Inc. has a beta of 1.302, which suggesting that the stock is 30.201% more volatile than S&P 500. In comparison Avidity Biosciences, Inc. has a beta of 0.930, suggesting its less volatile than the S&P 500 by 7.042%.
-
Which is a Better Dividend Stock DYN or RNA?
Dyne Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Avidity Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dyne Therapeutics, Inc. pays -- of its earnings as a dividend. Avidity Biosciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DYN or RNA?
Dyne Therapeutics, Inc. quarterly revenues are --, which are smaller than Avidity Biosciences, Inc. quarterly revenues of $12.5M. Dyne Therapeutics, Inc.'s net income of -$108M is higher than Avidity Biosciences, Inc.'s net income of -$174.4M. Notably, Dyne Therapeutics, Inc.'s price-to-earnings ratio is -- while Avidity Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dyne Therapeutics, Inc. is -- versus 458.78x for Avidity Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DYNDyne Therapeutics, Inc.-- -- -- -$108M RNAAvidity Biosciences, Inc.458.78x -- $12.5M -$174.4M
-
Which has Higher Returns DYN or SRPT?
Sarepta Therapeutics, Inc. has a net margin of -- compared to Dyne Therapeutics, Inc.'s net margin of -45.06%. Dyne Therapeutics, Inc.'s return on equity of -64.85% beat Sarepta Therapeutics, Inc.'s return on equity of -20.67%.
Company Gross Margin Earnings Per Share Invested Capital DYNDyne Therapeutics, Inc.-- -$0.76 $812.2M SRPTSarepta Therapeutics, Inc.57.63% -$1.80 $2.6B -
What do Analysts Say About DYN or SRPT?
Dyne Therapeutics, Inc. has a consensus price target of $39.13, signalling upside risk potential of 144.53%. On the other hand Sarepta Therapeutics, Inc. has an analysts' consensus of $21.43 which suggests that it could grow by 23.19%. Given that Dyne Therapeutics, Inc. has higher upside potential than Sarepta Therapeutics, Inc., analysts believe Dyne Therapeutics, Inc. is more attractive than Sarepta Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DYNDyne Therapeutics, Inc.11 2 0 SRPTSarepta Therapeutics, Inc.7 14 3 -
Is DYN or SRPT More Risky?
Dyne Therapeutics, Inc. has a beta of 1.302, which suggesting that the stock is 30.201% more volatile than S&P 500. In comparison Sarepta Therapeutics, Inc. has a beta of 0.393, suggesting its less volatile than the S&P 500 by 60.731%.
-
Which is a Better Dividend Stock DYN or SRPT?
Dyne Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dyne Therapeutics, Inc. pays -- of its earnings as a dividend. Sarepta Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DYN or SRPT?
Dyne Therapeutics, Inc. quarterly revenues are --, which are smaller than Sarepta Therapeutics, Inc. quarterly revenues of $399.4M. Dyne Therapeutics, Inc.'s net income of -$108M is higher than Sarepta Therapeutics, Inc.'s net income of -$179.9M. Notably, Dyne Therapeutics, Inc.'s price-to-earnings ratio is -- while Sarepta Therapeutics, Inc.'s PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dyne Therapeutics, Inc. is -- versus 0.74x for Sarepta Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DYNDyne Therapeutics, Inc.-- -- -- -$108M SRPTSarepta Therapeutics, Inc.0.74x 20.50x $399.4M -$179.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 64x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
42
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 29x
Alerts
Sell
17
ICLR alert for Feb 13
ICON plc [ICLR] is up 15.9% over the past day.
Buy
67
CGNX alert for Feb 13
Cognex Corp. [CGNX] is up 0.31% over the past day.
Buy
77
IPGP alert for Feb 13
IPG Photonics Corp. [IPGP] is up 2.47% over the past day.
